Pharmaceutical Technology

FEBRUARY 13, 2023

The first concept for a PROTAC was published in 2001, and recently these protein degraders have gained rapid momentum as a promising novel modality. This makes early R&D less risky, as many lead compounds are discontinued due to inadequate pharmacokinetic profiles and require excessively high dosages to be pharmaceutically active.

Dosage 59

Dosage Chemotherapy Compounding Immunity 59

The Thyroid Pharmacist

NOVEMBER 4, 2022

While the human body (via the liver and kidneys) can produce up to 4 g/day of inositol, it has been found that the overly processed, high glucose (and low fiber) Western diets that many people follow, only provide about 1 g/day of the compound. (7). Some people actually went into remission after starting the myo-inositol. Endokrynol Pol.

Diabetes 98

Diabetes Dosage Compounding Immunity 98

The Thyroid Pharmacist

SEPTEMBER 20, 2024

Chemotherapy agents: Chemotherapy agents can lead to constipation in a variety of ways such as slowing the movements of the intestinal tract or creating inflammation that disrupts digestive function. Chemotherapy-Induced Constipation and Diarrhea: Pathophysiology, Current and Emerging Treatments. Published January 2001.

Health and Personal Care Stores 67

Health and Personal Care Stores Diabetes Chemotherapy Medication Therapy Management (MTM) 67

FDA Law Blog: Biosimilars

FEBRUARY 11, 2024

Not surprisingly, then-presidential candidate Asa Hutchinson, DEA Administrator from 2001 to 2003, did not sign the letter. The letter is signed by six former DEA administrators and five former Directors of National Drug Policy. The earliest tenured is John Bartels, who served as Administrator from 1973 to 1975.

Controlled Substances 57

Controlled Substances Chemotherapy Compounding 57